Vitamin A Palmitate

Reinventing Vitamin A for neonatal and pediatric unmet medical needs Bronchopulmonary Dysplasia (BPD) is most frequent serious complication of preterm birth – US preterm births highest in 15 years Advent plans FDA PDUFA Meeting late-2023 to establish pathway for US approval of lead injectable product DOYLESTOWN, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Advent Therapeutics, Inc., a late-stage biotechnology company developing precisely optimized retinol palmitate (vitamin A) drug products as both injectable and breakthrough non-invasive inhaled neonatal lung therapies, announced today that it has received U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Designation (RPDD) for its vitamin A metabolic and reparative respiratory drugs for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants. FDA’s Rare Pediatric Disease Designation and Priority Voucher Program is intended to facilitate the development of new drugs for the prevention and treatment of rare pediatric diseases. Companies that receive approval for a New Drug Application (NDA) for a rare pediatric disease may be eligible for a voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product or sold to another sponsor for priority review of their marketing application. This program is intended to encourage the development of new drugs and biologics for the treatment of rare pediatric diseases. “We are acutely focused on BPD as an area of high unmet medical need that presently has no FDA-approved therapies for prevention or treatment. The FDA Rare Pediatric Disease Designation is an important addition to the Orphan Drug designations previously granted by the US FDA and the European EMA for our vitamin A metabolic and reparative respiratory drugs,” said Dave L. Lopez, CEO of Advent Therapeutics. ABOUT BPD BPD is a rare disease and the most common serious complication facing premature infants, resulting in significant morbidity and mortality. It is an extremely costly respiratory disorder afflicting premature infants for which there is currently no approved drugs worldwide. Annually, in both US and Europe, there are approximately 100,000 premature infants at-risk for BPD and many more in Asia-Pacific, Latin America and throughout the world. In the US, hospital costs for treating a BPD infant in the first year average $442,000 with an average hospital stay of 103 days. US healthcare costs of treating babies with BPD have been estimated as approaching $2.5 billion per year. FORWARD LOOKING STATEMENTS This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Media and investor contact: David L. Lopez david.lopez@advent-therapeutics.com

Bronchopulmonary dysplasia is a rare disease impacting premature infants. Credit: Ro_Ma_Li / Shutterstock.com. Advent Therapeutics has received a small business innovation research grant worth $3m from the US National Institutes of Health (NIH) to develop a non-invasive inhaled bronchopulmonary dysplasia (BPD) therapy. The Phase IIB grant will aid the company in developing an aerosolised formulation of vitamin A for the prevention of BPD, a rare but major respiratory condition impacting premature infants. Treatment is expensive, with no therapies yet approved. Recommended Reports Reports LOA and PTSR Model - Paclitaxel in Metastatic Adenocarcinoma of The Pancreas GlobalData Reports LOA and PTSR Model - Talimogene Laherparepvec in Metastatic Adenocarcinoma of The Pancreas GlobalData View all Companies Intelligence Advent LLC Advent Therapeutics Inc ODD View all Advent plans to commercialise the new formulation in 2025. The company will also use the grant to conclude preclinical requisites and scale up the production of inhalable retinol palmitate products to enter clinical trials in humans. This will aid in obtaining marketing approvals in the US and other regions. The vitamin A formulation has received orphan drug designation (ODD) in the US and Europe. The granting of ODD provides incentives including support to develop drugs and user fee exemption. Advent Therapeutics CEO David Lopez stated: “This NIH award will allow us to greatly accelerate the development and advance towards approval of our optimised vitamin A drug product. “Advent’s novel, precisely optimised products are intended to address the unmet medical needs of premature infants [with BPD] and reduce morbidity and mortality in this fragile patient population. “Our primary focus is to accelerate the path to commercialisation, first in the US, then EU and worldwide.” The latest funding takes the NIH grant received by Advent to more than $6m for its neonatal programmes.